Effects of Bosentan on the Skin Temperature of Hands and Feet in Patients with Connective Tissue Diseases Complicated with Raynauds Phenomenon: A Prospective, Open-Label, Uncontrolled, Single-Center Study

Yuji Akiyama

Authors

Yuji Akiyama

Keywords:

digital ulcers, endothelin receptor antagonist, pulmonary arterial hypertension, secondary Raynaud#x2019;s phenomenon, systemic sclerosis, thermography

Abstract

Abstract not found

Downloads

How to Cite

Effects of Bosentan on the Skin Temperature of Hands and Feet in Patients with Connective Tissue Diseases Complicated with Raynauds Phenomenon: A Prospective, Open-Label, Uncontrolled, Single-Center Study. (2015). Global Journal of Medical Research, 15(F2), 7-15. https://medicalresearchjournal.org/index.php/GJMR/article/view/900

Download Citation

References

Masashi Yanagisawa, Hiroki Kurihara, Sadao Kimura, Yoko Tomobe, Mieko Kobayashi, Youji Mitsui, Yoshio Yazaki, Katsutoshi Goto, Tomoh Masaki (1988) A novel potent vasoconstrictor peptide produced by vascular endothelial cells. 332(6163), 411-415.

Sohita Dhillon (2009) Bosentan. 69(14), 2005-2024.

Y Shirai, H Yasuoka, Y Okano, T Takeuchi, T Satoh, M Kuwana (2012) Clinical characteristics and survival of Japanese patients with connective tissue disease and pulmonary arterial hypertension: a singlecenttre cohort. 51(10), 1846-1854.

M Vayssairat, French (1996) Microcirculation Society Multicentre Group for the Study of Vascular Acrosyndromes. Controlled multicenter double blind trial of an oral analog of prostacyclin in the treatment of primary Raynaud's phenomenon. 23, 1917-1920.

M Hettema, D Zhang, H Bootsma, Cgm Kallenberg (2007) Bosentan therapy for patients with severe Raynaud's phenomenon in systemic sclerosis. 66, 1398-1399.

Masanori Funauchi, K Kishimoto, H Shimazu, Y Nagare, S Hino, T Yano, K Kinoshita (2009) Effects of bosentan on the skin lesions: an observational study from a single center in Japan. 29(7), 769-775.

N Giordano, L Puccetti, P Papakostas, N Dipietra, F Bruni, A Pasqui (2010) Bosentan treatment for Raynaud's phenomenon and skin fibrosis in patients with systemic sclerosis and pulmonary arterial hypertension: An open-label, observational, retrospective study. 23(4), 1185-1193.

V Nguyen, K Eisendle, I Gruber, B Hugl, D Reider, N Reider (2010) Effect of the dual endothelin receptor antagonist bosentan on Raynaud's phenomenon secondary to systemic sclerosis: a double-blind prospective, randomized, placebo-controlled pilot study. 49(3), 583-588.

Edoardo Rosato, Ilenia Molinaro, Federica Borghese, Carmelina Rossi, Simonetta Pisarri, Felice Salsano (2010) Bosentan Improves Skin Perfusion of Hands in Patients with Systemic Sclerosis with Pulmonary Arterial Hypertension. 37(12), 2531-2539.

T Moore, A Vail, A Herrick (2007) Assessment of digital vascular structure and function in response to bosentan in patients with systemic sclerosis-related Raynaud's phenomenon. 46(2), 363-364.

S Parisi, C Peroni, A Lagana, M Scarati, F Ambrogio, M Bruzzone, E Fusaro (2013) Efficacy of ambrisentan in the treatment of digital ulcers in patients with systemic sclerosis: a preliminary study. 52(6), 1142-1144.

A Masi (1980) Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classication of systemic sclerosis (scleroderma). 23(5), 581-590.

E Tan, A Cohen, J Fries, A Masi, D Mcshane, N Rothfield (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus (SLE). 25(11), 1271-1277.

R Kasukawa, T Nishimaki, T Takagi, S Miyawaki, R Yokohari, T Tsunematsu (1988) Pulmonary hypertension in connective tissue disease. Clinical analysis of sixty patients in multi-institutional study. 9(1), 56-62.

A Bohan, J Peter (1975) Polymyositis and dermatomyositis. 292, 403-407.

Richard Rodeheffer, James Rommer, Fredrick Wigley, Craig Smith (1983) Controlled Double-Blind Trial of Nifedipine in the Treatment of Raynaud's Phenomenon. 308(15), 880-883.

B Coleiro, S Marshall, C Denton, K Howell, A Blann, K Welsh, C Black (2001) Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine. 40(9), 1038-1043.

Y Akiyama, S Ohno, T Asaoka, T Katagiri, M Takeishi, H Omata (2001) The combination therapy with sarpoglerate hydrochloride and kampo medicine (Oren-gedoku-to or Toki-shakuyaku-san) for Raynaud's phenomenon. 51(5), 1101-1108.

M Ramos-Casals, P Brito-Zeron, N Nardi, G Claver, G Risco, F Parraga (2004) Successful treatment of severe Raynaud's phenomenon with bosentan in four patients with systemic sclerosis. 43, 1454-1456.

N Selenko-Gebauer, N Duschek, G Minimair, G Stingl, F Karlhofer (2006) Successful treatment of patients with severe secondary Raynaud's phenomenon with the endothelin receptor antagonist bosentan. 45(Supplement 3), iii45-iii48.

Padmanabha Shenoy, Sudeep Kumar, Lalan Jha, Sunil Choudhary, Uttam Singh, Ramnath Misra, Vikas Agarwal (2010) Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. 49(12), 2420-2428.

Matthieu Roustit, Sophie Blaise, Yannick Allanore, Patrick Carpentier, Evren Caglayan, Jean-Luc Cracowski (2013) Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud's phenomenon: systematic review and meta-analysis of randomised trials. 72(10), 1696-1699.

Claudio Corallo, Maurizio Cutolo, Bashar Kahaleh, Gianluca Pecetti, Antonio Montella, Chiara Chirico, Stefano Soldano, Ranuccio Nuti, Nicola Giordano (2013) Bosentan and macitentan prevent the endothelial-to-mesenchymal transition (EndoMT) in systemic sclerosis: in vitro study. 18(1), 455-462.